Acute Hepatitis C remains a significant global health challenge, with a need for effective and safe antiviral treatments. The objective of this study was to evaluate the efficacy and safety of a novel class of antiviral agents in treating acute Hepatitis C infections. A randomized, double-blind, placebo-controlled clinical trial was conducted across multiple international centers. Participants aged 18-65 with confirmed acute Hepatitis C were enrolled and randomly assigned to receive either the novel antiviral agents or a placebo for 12 weeks. The primary endpoint was the sustained virological response rate at week 24 post-treatment. Secondary endpoints included safety profiles and quality of life assessments. The study demonstrated a statistically significant higher sustained virological response in the treatment group compared to the placebo group, with 85% versus 30%, respectively. Adverse events were mild and comparable between both groups. The findings suggest that these novel antiviral agents are highly effective and safe in treating acute Hepatitis C, offering a promising alternative to existing therapies. Further studies are recommended to confirm long-term outcomes and explore their use in diverse patient populations.